iBio Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals-ADAR1 Partners, LP(9.27%),ADAR1 Capital Management, LLC(9.27%), etc.
iBio Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals
iBio Inc | SC 13G：超過5%持股股東披露文件
牛牛AI助理已提取核心訊息
On April 5, 2024, a Schedule 13G filing was made with the United States Securities and Exchange Commission (SEC) indicating that ADAR1 Partners, LP, along with related entities and Daniel Schneeberger, collectively reported a 9.27% ownership stake in iBio Inc. The shares in question amount to 789,293 shares of common stock. ADAR1 Partners, LP is directly holding the shares, while ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, both managed by Daniel Schneeberger, may be deemed to indirectly beneficially own the securities. The filing, which is based on the number of shares outstanding as reported on April 1, 2024, does not imply any intention to change or influence the control of iBio Inc. The principal business office for the reporting persons is located in Austin, Texas, and the filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934.
On April 5, 2024, a Schedule 13G filing was made with the United States Securities and Exchange Commission (SEC) indicating that ADAR1 Partners, LP, along with related entities and Daniel Schneeberger, collectively reported a 9.27% ownership stake in iBio Inc. The shares in question amount to 789,293 shares of common stock. ADAR1 Partners, LP is directly holding the shares, while ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, both managed by Daniel Schneeberger, may be deemed to indirectly beneficially own the securities. The filing, which is based on the number of shares outstanding as reported on April 1, 2024, does not imply any intention to change or influence the control of iBio Inc. The principal business office for the reporting persons is located in Austin, Texas, and the filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934.
2024年4月5日，向美國證券交易委員會（SEC）提交了附表13G文件，表明ADAR1 Partners、LP以及關聯實體和丹尼爾·施內伯格共同報告了iBio Inc.9.27％的所有權。有關股票共計789,293股普通股。ADAR1 Partners, LP直接持有股份，而由丹尼爾·施內伯格管理的 ADAR1 資本管理有限責任公司和 ADAR1 資本管理GP, LLC可能被視爲間接實益擁有這些證券。該文件基於2024年4月1日報告的已發行股票數量，並不意味着有任何改變或影響iBio Inc.控制權的意圖。申報人的主要業務辦公室位於德克薩斯州的奧斯汀，該申報是根據1934年《證券交易法》第13d-1（b）條提交的。
2024年4月5日，向美國證券交易委員會（SEC）提交了附表13G文件，表明ADAR1 Partners、LP以及關聯實體和丹尼爾·施內伯格共同報告了iBio Inc.9.27％的所有權。有關股票共計789,293股普通股。ADAR1 Partners, LP直接持有股份，而由丹尼爾·施內伯格管理的 ADAR1 資本管理有限責任公司和 ADAR1 資本管理GP, LLC可能被視爲間接實益擁有這些證券。該文件基於2024年4月1日報告的已發行股票數量，並不意味着有任何改變或影響iBio Inc.控制權的意圖。申報人的主要業務辦公室位於德克薩斯州的奧斯汀，該申報是根據1934年《證券交易法》第13d-1（b）條提交的。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了